尿血安合剂联合来氟米特治疗IgA肾病安全性及对患者VEGF、NF-κB表达的影响

The effect of hematuria ann mixture combined with leflunomide on IgA nephropathy patients safety and VEGF,NF-kB expression

目的:尿血安合剂联合来氟米特对IgA肾病患者安全性及VEGF、NF-κB表达的影响。方法:选择我院收治的90例IgA肾病患者作为本次研究对象,并分为45例对照组予来氟米特口服;45例观察组在来氟米特加尿血安合剂。观察两组患者安全性及VEGF、NF-κB表达。结果:治疗后对照组及观察组BUN分别为(6.32±1.26)mmo1/L及(5.23±1.21)mmo1/L,Scr分别为(75.32±12.52)μmo1/L及(71.62±13.34)μmo1/L,24hUP分别为(85.96±5.63)mg/24h及(46.92±4.52)mg/24h,Ccr分别为(44.51±5.16)ml/min及(44.51±5.16)ml/min,均显著低于治疗前(P<0.05),两组比较,观察组肾功能显著优于对照组(P<0.05)。治疗后对照组及观察组尿蛋白分别为(1.96±0.75)g/d及(0.92±0.67)g/d,尿红细胞分别为(131.32±42.85)个/μl及(79.64±38.36)个/μl,均较治疗前有改善,两组比较,观察组尿蛋白及尿红细胞情况优于对照组(P<0.05)。治疗后对照组ALT为(68.36±6.75)U/L,较治疗前有显著升高(P<0.05),而观察组ALT为(30.61±5.72),与治疗前无显著变化(P>0.05),且显著优于对照组水平(P<0.05)。治疗后对照组及观察组WBC分别为(4.92±1.13)×109及(4.99±0.86)×109,均较治疗前无显著变化(P>0.05),两组比较,两组治疗后WBC水平无统计学差异(P>0.05)。治疗后对照组及观察组VEGF表达分别为(39.31±8.34)pg/ml及(28.20±11.64)pg/ml,NF-kB分别为(11.08±2.83)ng/ml及(6.58±2.19)ng/ml,均显著低于治疗前(P<0.05),两组比较,观察组VEGF及NF-kB表达均显著优于对照组(P<0.05)。结论:尿血安合剂联合来氟米特治疗IgA肾病安全性高,疗效显著,能显著改善VEGF及NF-Κb表达。

Objective：To explore the effect of hematuria ann mixture combined with leflunomide on IgA nephropathy patients safety and VEGF,NF-K B expression.Methods：90 cases of IgA nephropathy patients in our hospital divided into 45 cases of control group with random number table.Methods：To treat oral leflunomide;45 cases of the observation group：in the control group on the basis of an increase of hematuria mixture in the treatment of.The safety of the two groups and the expression of VEGF and NF-kB were observed.Results：After treatment,two groups of BUN,Scr,24 hUP,renal function indexes were significantly lower than those before treatment（P〈0.05）,the Ccr index of the two groups of renal function were significantly higher than those before treatment（P〈0.05）.After the treatment,the observation group after treatment control of the renal function index were significantly better than group（P〉0.05）.Two groups of patients with urinary protein and red blood cells were significantly decreased,and the observation group decreased significantly than the control group（P〉0.05）.The observation of liver function,blood group before and after treatment there were no significant statistical differences in meaning（P〈0.05）,the control group of liver function before and after treatment were significantly higher,and the observation group was significantly higher than that of after treatment（P〉0.05）.The two groups of patients after treatment,VEGF and NF-K B expression was better than that before treatment,the difference was statistically sig nificant（P〈0.05）,comparison between groups,the observation group after the treatment of VEGF and NF-K B It was significantly better than the control group（P〈0.05）.Conclusion：Hematuria ann mixture combined with leflunomide in the treatment of IgA nephropathy with high safety,obvious curative effect,can significantly improve VEGF and NF-K B expression,which is worthy of clinical promotion.